Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings ...

Jahani-Asl’s team found evidence that the drug — called edaravone — shows promise in suppressing the self-renewing cancerous ...

The analyses offer evidence for a slowing of functional decline and improved survival outcomes with long-term Radicava ORS by ALS patients.

NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by ...

Edaravone dexborneol, a brain cell protection was used before EVT, and the proportion of patients with functional score 2 below 90 days was 55.0% vs. 49.6% compared with placebo, which was ...

Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...

No other ALS treatment appeared until 2017, when the FDA approved the novel antioxidant edaravone (Radicava). In 2022, the agency approved an oral suspension version, but a study published that ...

胶质母细胞瘤是侵袭性脑肿瘤，中位生存期仍不到22个月。FDA批准的ALS药物Edaravone能抑制iNOS信号，而iNOS信号是脑肿瘤干细胞的关键调节因子。基于此，加拿大研究人员发现Edaravone在临床前模型的治疗延迟了胶质母细胞瘤的发生，并延长临床前模型的寿命 ...